Purpose. To evaluate whether the pouchitis disease activity index (PDAI) alone is suffi cient to select appropriate treatment plans for ulcerative colitis patients with bowel movement problems following ileal pouch-anal anastomosis (IPAA). Methods. The study included 70 patients undergoing an IPAA. For these patients, an evaluation by PDAI was performed prospectively at 1-2 years after the ileostomy closure. When the symptoms relevant to bowel movement appeared, PDAI was evaluated and metronidazole or ciprofl oxacin was administered. Pouchitis was diagnosed in patients with PDAI scores of 7 or higher. The patients whose PDAI score was less than 7 and who responded to antibiotic therapy were defi ned as treatment responders having disease not diagnosed by PDAI (TR-NDPDAI). Results. Pouchitis was diagnosed in 16 of the 70 enrolled patients (22.9%) using the PDAI scoring system. Of these 16 patients, 11 had acute pouchitis and 5 had chronic pouchitis. Twenty-one patients whose PDAI score was less than 7 were symptomatic. Among them, 12 were TR-NDPDAI. In patients with TR-NDPDAI, antibiotic treatment resulted in signifi cant improvements in the PDAI score (P < 0.001) and in clinical symptoms (P < 0.001) after treatment. Conclusion. Antibiotic treatment was effective in a considerable number of ulcerative colitis patients whose PDAI score was less than 7 after IPAA.
Introduction
Since ileal pouch-anal anastomosis (IPAA) was fi rst described, 1 IPAA has become the preferred surgical technique for the treatment of ulcerative colitis (UC). While the surgical advancements for IPAA have reduced the short-term morbidity, long-term complications, such as pouchitis 2 , small bowel obstruction, 3 and portal vein thrombi 4 persist as problematic issues. Pouchitis is an idiopathic infl ammatory disease of the ileal reservoir that may occur after IPAA. The frequency of pouchitis varies from 7% to 59%. 4, 5 There are no universal diagnostic criteria, and any differences in the diagnostic criteria between institutions may account for the wide range of occurrence. The pouchitis disease activity index (PDAI) was proposed by the Mayo Clinic and has three components as follows: clinical symptoms, endoscopic fi ndings, and pathological fi ndings. 6 A diagnosis of pouchitis made from only the subjective measures of disease activity, such as the symptoms, may lead to an overassessment. 2, 6 Therefore, the incorporation of objective data such as endoscopic and pathological fi ndings is considered necessary for an accurate evaluation. The PDAI was therefore found to have the more widely used criteria for the diagnosis of pouchitis and a preferable tool for its clinical study.
However, the diagnostic ability of the PDAI itself is diffi cult to assess because an absolute diagnosis of pouchitis cannot be made using other diagnostic criteria. 7 In addition, the information from the PDAI does not provide a clear diagnosis and prediction of the best treatment. Pouchitis is often not diagnosed using the PDAI, even in symptomatic patients. Antibiotic therapy is successful in some of these patients not diagnosed by PDAI. 2, 8 The objective of the current study was to examine whether PDAI alone was suffi cient to design a treatment strategy for symptomatic patients after IPAA. Two indices, the PDAI and the response to antibiotics, were used to classify patients who had IPAA and who exhibited bowel movement symptoms.
Patients and Methods

Study Population
The subjects were selected from all patients who had undergone a total colectomy and IPAA for UC with simultaneous temporary ileostomy between January 1997 and December 2003 at the First Department of Surgery, Hiroshima University, and for whom 1-2 years had elapsed since the ileostomy closure. None of these patients had been previously diagnosed with pouchitis by PDAI. Patients were excluded if they were 12 years of age or younger, took antibiotics recently (within 2 weeks before they entered this study), had infection enteritis, or were suspected of having Crohn's disease postoperatively or had any nonfunctioning ileal pouches (e.g., patients with evacuation tubes).
Study Design
Outpatient endoscopy was performed on the patients with or without symptoms 1-2 years after the closure of the ileostomy to evaluate the infl ammatory changes of the pouch. A prospective evaluation was performed on the endoscopic fi ndings of ileal pouch mucosa and on the pathological fi ndings from a biopsy. In addition, for patients whose bowel movement symptoms worsened during the study period, an evaluation by PDAI was performed and 750 mg/day metronidazole or 1000 mg/day ciprofl oxacin was orally administered for 14 days. The worsening of symptoms was defi ned as an increase in the PDAI symptoms score of one or greater points. The daily recommended dose of metronidazole is 1200 mg or 15-20 mg/kg. 9 However, we set the dose of metronidazole at 750 mg/day, because UC patients in Japan weigh less than patients in Europe or the United States, and Japanese patients tend to have more gastrointestinal symptoms at the dose used in Europe or the United States. The protocol for this study was conducted with written consent from each participant.
Method of Diagnosis of Pouchitis
The clinical symptoms, endoscopic fi ndings, and pathological fi ndings were assigned scores using the PDAI as proposed by the Mayo Clinic. 6 The PDAI has three components: clinical symptoms, endoscopic fi ndings, and pathological fi ndings. The highest score for each component is 6, and a total score of 7 is considered indicative of pouchitis (PDAI-diagnosed pouchitis). The patients were interviewed and their clinical symptoms were scored during their outpatient visits by the same physician. Endoscopies were performed by one of the three specifi ed endoscopists. The fi lms taken during endoscopy were examined and used to evaluate the endoscopic fi ndings. During the endoscopies, biopsies were taken from the pouches with or without any particular fi ndings of infl ammation. The pathological fi ndings were re-examined and scored at the same time in a blinded fashion by one pathologist.
A PDAI endoscopy score of 1 or higher was defi ned as indicative of positive endoscopic fi ndings, a PDAI pathological score of 3 or higher as indicative of positive pathological fi ndings, and a clinical score of 1 or higher as indicative of positive clinical fi ndings.
Defi nition of Pouchitis, TR-NDPDAI, Cuffi tis, and Irritable Pouch Syndrome
The therapeutic effects were evaluated by examining the changes in clinical symptom during the 2 weeks following the initiation of antibiotic treatment for the symptomatic patients. The outcome was evaluated by PDAI, which is based on the symptomatic, endoscopic, and pathological fi ndings ( Table 1 ). The patients were defi ned as treatment responders having disease not diagnosed by PDAI if they responded to antibiotics and their PDAI scores were less than 7 (TR-NDPDAI). The responsiveness in TR-NDPDAI was defi ned as a reduction in the PDAI symptoms score by one or more points within 2 weeks after the antibiotic treatment. Cuffi tis was diagnosed in patients with a PDAI score of less than 7 and with signifi cant infl ammatory fi ndings in the residual rectum. Irritable pouch syndrome (IPS) was diagnosed in nonresponders with a PDAI score of less than 7 who underwent a mucosectomy or had no infl ammatory changes in the residual rectum. 
Statistical Analysis
A Chi-square test was used for the categorical data (comparisons of patient background data). Student's ttest was used for continuous data. The Mann-Whitney U-test was used to compare the scores of each PDAI component between the two groups. A comparison between before and after the antibiotic treatment was performed for every component using Wilcoxon's test. Logistic regression models were used to determine which components were signifi cantly related to PDAI scores less than 7 in TR-NDPDAI in comparison to pouchitis. A P value of 0.05 or less was considered to be statistically signifi cant. All data are indicated as the mean ± standard deviation.
Results
Within the study period, 102 patients underwent surgeries for UC. Each surgery was performed by the same surgeons. A hand-sewn IPAA with a mucosectomy was performed in 65 patients and a double-stapled technique was used in 5 patients. In 20 patients and 12 patients, we were unable to obtain consent to perform postsurgical endoscopy and biopsies during endoscopy, respectively. All of these patients were asymptomatic. Therefore, a total of 32 patients were excluded, and the remaining 70 patients were entered into the study. The median follow-up period at the endoscopic examination in these 70 patients was 22 months (range, 12-81 months) after the ileostomy closure.
Among the 70 patients, 37 (52.9%) were symptomatic, all of whom were treated with antibiotics. The treatment was successful in 23 of these 37 patients. Of the 70 patients, 16 (22.9%) had PDAI-diagnosed pouchitis (PDAI scores of 7 or higher); however, the occurrence rate was 15.7% of the 102 eligible patients, including the asymptomatic patients who did not consent to the endoscopic examinations and biopsies. There were 12 TR-NDPDAI (8 with positive endoscopic fi ndings [>1 point] and 4 with positive pathological fi ndings [>3 points]). Six of the 12 patients were unaware of the worsening of their symptoms because the deterioration was gradual. We found that their symptoms were worsening only after checking previous data in their medical records. Of the 12 TR-NDPDAI, 8 (67%) had objective evidence based on endoscopy and 4 (33%) had objective evidence based on the pathological fi ndings. Table 2 shows the demographic characteristics of all study patients. There were no signifi cant differences between the three groups with respect to age, gender, the duration of disease before surgery, dose of steroid, or surgical indication. Figure 1 shows the diagnostic tree for each patient group. Of the 16 PDAI-diagnosed pouchitis patients, 11 had acute pouchitis and 5 had chronic pouchitis. Of the 37 symptomatic patients, 21 had PDAI scores of less than 7; 12 of these 21 patients were TR-NDPDAI and 9 were nonresponders. Furthermore, 2 of these 9 patients had cuffi tis and the other 7 patients had IPS. During the study period, 33 patients were asymptomatic and therefore were not suspected of having pouchitis that required treatment. The PDAI score was 2.8 ± 1.1 for the asymptomatic patients and 6.9 ± 2.8 for the symptomatic patients (P < 0.001). Figure 2 shows the changes in the pretreatment and post-treatment scores of 12 TR-NDPDAI patients. The PDAI score and the clinical symptom score showed a signifi cant improvement (total PDAI score, 5.0 ± 1.1 vs 3.2 ± 1.1 [P = 0.002]; clinical symptoms score, 1.6 ± 0.8 Values reported are mean ± one standard deviation PDAI, pouchitis disease activity index; TR-NDPDAI, treatment responders having disease not diagnosed by PDAI P value represents the results of the Mann-Whitney U-test vs 0.2 ± 0.4 [P = 0.002]). Since the scores for the endoscopic fi ndings were initially low in TR-NDPDAI, there was no signifi cant improvement observed after the treatment (1.0 ± 1.0 vs 0.8 ± 1.1; P = 0.157). In addition, the scores for the pathological fi ndings did not reveal any improvement (2.4 ± 0.7 vs 2.2 ± 0.4; P = 0.083). The mean total PDAI score and each component score in the patients with PDAI-diagnosed pouchitis and in TR-NDPDAI are compared in Table 3 . There were no signifi cant differences between the two groups with respect to their clinical symptoms score (2.7 ± 1.4 vs 1.9 ± 0.8; P = 0.103). However, TR-NDPDAI had signifi cantly lower scores for the endoscopic and pathological fi ndings (endoscopic fi ndings: 3.3 ± 1.7 vs 1.0 ± 1.0 [P = 0.001]; pathological fi ndings: 3.5 ± 0.9 vs 2.4 ± 0.7 [P = 0.003]). The contributor to the low PDAI score in TR-NDPDAI was the particularly low score for the endoscopic and pathological fi ndings.
In the univariate logistic regression models, the scores for the endoscopic and pathological fi ndings were the main predictors of a PDAI score 7 Table 4 shows the scores of the subgroups that were classifi ed on the basis of the PDAI score and response to antibiotics. There was no signifi cant difference in the PDAI score between the TR-NDPDAI and IPS groups (5.3 ± 0.7 vs 5.2 ± 1.1; P = 0.857). There was a signifi cant difference only in the clinical symptoms score (1.9 ± 0.8 vs 1.1 ± 0.4; P = 0.028), but not in the objective scores for the endoscopic fi ndings (1.0 ± 1.0 vs 1.3 ± 1.3; P = 0.505) or pathological fi ndings (2.4 ± 1.7 vs 2.8 ± 0.9; P = 0.253).
There was also no signifi cant difference in the pathological fi ndings between the TR-NDPDAI and asymptomatic patients (2.4 ± 1.7 vs 2.5 ± 0.7; P = 0.890). The clinical symptoms and endoscopic fi ndings scores were signifi cantly higher in TR-NDPDAI than in the asymptomatic patients (symptoms: 1.9 ± 0.8 vs 0.0 ± 0.0 [P < 0.001]; endoscopic fi ndings: 1.0 ± 1.0 vs 0.3 ± 0.6 [P = 0.015]). In the two cases of cuffi tis, the endoscopic fi ndings score was 0.
Discussion
Various problems have been identifi ed in the PDAI, 6-9,11-13 and some have proposed that the objective fi ndings such as endoscopy and pathology should be emphasized more than the subjective assessment of clinical symptoms. 9, 11 On the other hand, in one report the clinical symptoms of chronic pouchitis improved following treatment with metronidazole, while the objective (endoscopy and pathology) fi ndings did not, 13 thus suggesting that the therapeutic effect cannot effectively be determined from the objective fi ndings. Furthermore, various problems have been identifi ed in relating the assessment by the pathological fi ndings to the PDAI. 7, 12 Shen et al. stated that the sensitivity and specifi city of the modifi ed PDAI, which excludes the pathological fi ndings, should be accepted 7 and that biopsies are probably unnecessary from the viewpoint of economic effi ciency. 13 From the Japanese group, the Japanese criteria, which consisted of the clinical symptoms and endoscopic fi ndings and did not contain any pathological fi ndings and scoring system, have been proposed as more simple and useful criteria in clinical practice.
14 In this study, we selected the PDAI as having the most widely used criteria to evaluate the pathological fi ndings and severity.
Furthermore, Heuschen et al. 9 suggested that the cutoff of 7 points is too high for the diagnosis of pouchitis and that if the cutoff point were one or two points lower, the PDAI would be more accurate. In addition, a question has been raised with respect to the treatment of the patients with PDAI scores of less than 7 but who are responsive to antibiotics. 8 Therefore, in the current study we combined two indices (namely, the diagnosis using the PDAI and the estimation according to the response to antibiotics) and then subclassifi ed the symptomatic patients. We thus found a signifi cant number of cases in which antibiotic treatment was effective in patients with low PDAI scores. Of the 70 patients, 37 were symptomatic but only 16 had PDAI-diagnosed pouchitis. Of the remaining 21 symptomatic patients, 12 of 21 (57.1%) responded to antibiotics. Therefore, using the PDAI score (>7), 12 patients who were relieved of their symptoms by antibiotics were overlooked. Although the PDAI is a useful way of objectively quantifying the severity of pouchitis, it did not predict the success of treatment in our study.
We considered that TR-NDPDAI included symptomatic patients who were not diagnosed by the PDAI scoring system and the patients with proximal small bowel bacterial overgrowth. Multiple studies have shown that some patients with irritable bowel syndrome, analogous to IPS, have small bowel bacterial overgrowth, and this is thought to occur in 40% of the patients with ileal pouches. We examined where the differences in the PDAI scores lie between the TR-NDPDAI and the PDAIdiagnosed pouchitis group. Although no signifi cant difference was observed in the clinical symptoms, a large difference in the endoscopic and pathological fi ndings contributed to the difference in the total PDAI scores among these two groups. PDAI-diagnosed pouchitis occurred in 22.9% of all patients in this study and 15.7% of all eligible patients including those excluded because they did not give consent for endoscopy due to an absence of symptoms. Since some TR-NDPDAI may have pouchitis, the incidence of pouchitis may be higher than this value.
Shen et al. defi ned IPS by the presence of low PDAI scores in symptomatic patients and stated that the treatment for irritable bowel syndrome was successful in these patients, and reported that a very high frequency (42.6%) of symptomatic patients had IPS. 11 The frequency is high because IPS is a diagnosis that covers a wide range of nonspecifi c infl ammatory conditions with symptoms similar to pouchitis. 16 Instead, we classifi ed these symptomatic patients with a PDAI score of less than 7. The patients who were successfully treated with antibiotics were classifi ed as TR-NDPDAI (12 cases). Cuffi tis was diagnosed in patients not successfully treated with antibiotics who had infl ammation in the residual rectum and had normal endoscopic fi ndings in the pouch (2 cases). Irritable pouch syndrome was diagnosed in all the other patients (7 cases). Although we examined the differences between the TR-NDPDAI and nonpouchitis groups, in the objective fi ndings there was little difference between the TR-NDPDAI and nonpouchitis groups, as shown in Table 4 .
From the perspective of treatment, TR-NDPDAI patients must be differentiated from IPS patients. Therefore, in regard to the etiology we thought that the IPS was analogous to irritable bowel syndrome as Shen et al. described, 11 and TR-NDPDAI was analogous to pouchitis. Although TR-NDPDAI had slightly higher clinical symptom scores than IPS patients, the differences in the scores of total PDAI, endoscopic fi ndings, or pathological fi ndings were not signifi cant. Therefore, the differentiation between the two groups is diffi cult using the components of the PDAI. It may be a treatment option to administer anticholinergic or antidepressant agents to the symptomatic patients with PDAI scores less than 7 before the administration of antibiotics. However, it is not clear whether the treatment strategy for IPS would be less costly with fewer side effects than the use of antibiotics. At this time, we cannot recommend which treatment strategy should be initiated fi rst.
The benefi ts of a mucosectomy are the lower rates of infl ammation and dysplasia in the retained mucosa in UC. However, a recent meta-analysis suggested that nighttime seepage of stool, and resting and squeeze pressure were worse after a mucosectomy than stapled anastomosis. 17 A high percentage of patients undergoing a mucosectomy and hand-sewn anastomosis in this study may contribute to the high incidence of symptomatic patients other than PDAI-diagnosed pouchitis.
This study is limited by the absence of a placebo treatment arm to understand how much the extent of the improvement was due to antibiotics versus a mild random variation in the symptoms, especially in TR-NDPDAI. In conclusion, the PDAI was not a good indicator of the success of treatment in symptomatic patients who have undergone IPAA. A considerable number of symptomatic patients with PDAI scores less than 7 showed clinical improvement upon antibiotic treatment. Because the symptoms after IPAA had several causes, an investigation of appropriate treatment for each of the conditions is necessary. For this reason, we believe that a detailed analysis should be performed to develop treatment plans in symptomatic patients even if their PDAI scores are less than 7.
